Two new appointments at Camargo Pharmaceutical Services

VP, Scientific and Regulatory Affairs and Director, Contracts and Legal Projects

Camargo Pharmaceutical Services, a global drug development strategist specialising in the 505(b)(2) approval pathway, has appointed Marc Wiles as Vice President, Scientific and Regulatory Affairs, and Suzanne Beck as Director, Contracts and Legal Projects.

With more than 20 years of experience in drug development, Wiles brings extensive technical and regulatory expertise to Camargo in assessing, developing and registering therapeutic products.

Before joining Camargo, Wiles was General Manager and Regulatory Affairs Scientific Advisor at NDA Regulatory Science in the UK, where he was responsible for expanding the company’s US operations. He was also Director of Regulatory Affairs (Non-clinical and Clinical) and General Manager at ERA Consulting and Senior Vice President of Operations at ProImmune.

Suzanne Beck

Suzanne Beck

Beck brings legal and regulatory experience to Camargo having been an attorney for more than 15 years, including 10 years as a pharmaceutical document review attorney working across all phases of product development as well as pre- and post-marketing and FDA regulatory filings.

You may also like

Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Regulatory

4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA

The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
Regulatory

The key role of IVDs in healthcare: challenges to commercialisation and access

In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
Subscribe now